1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 1:Clinical parameters in patients with IIH before and after transverse sinus stent placement
Clinical Parameter Before Stent After Stent Mild Moderate Severe Mild Moderate Severe Papilledema 11a 27 7 0b 0 0 Visual acuity loss 4 4 5 3 1 0 Visual field loss 19c 6 5 5 2 0 Headache 6 22 15 0 8d 0 Transient visual obscurations 3 10 6 0 0 0 Pulsatile tinnitus 6 9 2 0 0 0 Diplopia 3 2 1 0 0 0
a One patient with optic atrophy.
b Four patients with optic atrophy.
c Twelve patients with only enlarged blind spots.
d Six patients who were re-stented.